AIM: To determine the difference in survival after cystectomy between patients presenting with primary muscle infiltrating bladder cancer and patients with progression to muscle infiltration after treatment for initial non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively analyzed the files of 188 patients who underwent cystectomy for transitional cell carcinoma between 1987 and 2005. Two groups were defined: patients presenting with muscle-invasive tumours and those progressing to muscle invasion after initial treatment. This second group was further divided into low-intermediate and high risk according to the EAU grouping for NMIBC. RESULTS: The 5-year disease specific survival (95% confidence intervals) for all patients was 50%(42-59%); 49%(40-60%) in the primary muscle infiltrating group and 52%(37-74%) in the progressive group (p = ns). The 5-year disease specific survival in the progressive group according to EAU risk groups was 75%(58-97%) for the initially diagnosed low-intermediate risk tumours and 35%(17-71%) for the initially diagnosed high-risk tumours (p = 0.015). The percentage of patients with non-locally confined tumours (pT3/4-N0//any pT-N+) was 31%//45% and 24%//46% in the primary muscle infiltrating and progressive group, respectively. CONCLUSIONS: Despite close observation of patients treated for non-muscle-invasive bladder cancer, the survival of patients who progress to muscle invasion is not better than survival of patients presenting with primary muscle infiltrating cancer. Patients with high-risk non-invasive tumours (EAU risk-categories) who progress to muscle-invasive disease have a worse prognosis compared to patients with low or intermediate risk tumours. Copyright (c) 2009 Elsevier Ltd. All rights reserved.
AIM: To determine the difference in survival after cystectomy between patients presenting with primary muscle infiltrating bladder cancer and patients with progression to muscle infiltration after treatment for initial non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively analyzed the files of 188 patients who underwent cystectomy for transitional cell carcinoma between 1987 and 2005. Two groups were defined: patients presenting with muscle-invasive tumours and those progressing to muscle invasion after initial treatment. This second group was further divided into low-intermediate and high risk according to the EAU grouping for NMIBC. RESULTS: The 5-year disease specific survival (95% confidence intervals) for all patients was 50%(42-59%); 49%(40-60%) in the primary muscle infiltrating group and 52%(37-74%) in the progressive group (p = ns). The 5-year disease specific survival in the progressive group according to EAU risk groups was 75%(58-97%) for the initially diagnosed low-intermediate risk tumours and 35%(17-71%) for the initially diagnosed high-risk tumours (p = 0.015). The percentage of patients with non-locally confined tumours (pT3/4-N0//any pT-N+) was 31%//45% and 24%//46% in the primary muscle infiltrating and progressive group, respectively. CONCLUSIONS: Despite close observation of patients treated for non-muscle-invasive bladder cancer, the survival of patients who progress to muscle invasion is not better than survival of patients presenting with primary muscle infiltrating cancer. Patients with high-risk non-invasive tumours (EAU risk-categories) who progress to muscle-invasive disease have a worse prognosis compared to patients with low or intermediate risk tumours. Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Authors: Ahmed F Kotb; Evan Kovac; Wassim Kassouf; Joe Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Armen G Aprikian Journal: World J Urol Date: 2012-12 Impact factor: 4.226
Authors: David D'Andrea; Shahrokh F Shariat; Francesco Soria; Andrea Mari; Laura S Mertens; Ettore Di Trapani; Diego M Carrion; Benjamin Pradere; Renate Pichler; Ronan Filippot; Guillaume Grisay; Francesco Del Giudice; Ekaterina Laukhtina; David Paulnsteiner; Wojciech Krajewski; Sonia Vallet; Martina Maggi; Ettore De Berardinis; Mario Álvarez-Maestro; Stephan Brönimann; Fabrizio Di Maida; Bas W G van Rhijn; Kees Hendricksen; Marco Moschini Journal: Eur Urol Open Sci Date: 2022-05-28
Authors: Mario Pones; David D'Andrea; Keiichiro Mori; Mohammad Abufraj; Marco Moschini; Eva Comperat; Shahrokh F Shariat Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639